{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/424021659"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "PHILADELPHIA???(BUSINESS WIRE)???Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA?? (pembrolizumab), the company???s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "globaltort.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/31464006"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/424021659"] } } }
